Organization
North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany
6 abstracts
Abstract
Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study.Org: Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany, Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany, Hospital Aschaffenburg GmbH, Aschaffenburg, Germany, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany,
Abstract
First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Stanford University School of Medicine, Institute for Biometry and Clinical Epidemiology, Hospital Universitario Virgen del Rocío, Sant'Anna Hospital,
Abstract
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,
Abstract
Patients with endometrial cancer: Expectations and preferences towards therapy and quality of life—First results of an international survey (NOGGO, ENGOT, GCIG - IMPROVE/EXPRESSION XI).Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany, Campus Virchow Klinikum, Charité - University Medicine of Berlin, Institute of Biometry and Clinical Epidemiology,
Abstract
Comprehensive HRD testing in epithelial ovarian cancer: A further step toward personalized therapy decisions.Org: Innsbruck Medical University; Department of Obstetrics and Gynecology, Innsbruck, Austria, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Innsbruck, Austria, Institute of Human Genetics, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany,
Abstract
Sexuality as a prognostic factor: Results of an individual participant data NOGGO-meta-analysis of 1,041 recurrent ovarian cancer patients before starting chemotherapy.Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Charité - University Medicine of Berlin, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany,